China’s National Medical Products Administration approved Eli Lilly’s oral weight-loss drug today: orforglipron calcium tablets, marketed under the brand name Foundayo, for long-term weight management in adults. It’s the first oral GLP-1 weight-loss drug approved in China—no injections, and you can take it at any time of day, with or without food or water. People who are afraid of needles finally have another option.
The drug launched in the U.S. first, in April this year, under the name Foundayo. Lilly said in its third-quarter earnings report that it had brought in $281 million since launch. Lilly shares closed above $1,400 last night, up just over 0.3%—barely moving. With a market cap of more than $1.2 trillion, it’s just sitting there waiting for tonight’s premarket trading to deliver a verdict.
The drug launched in the U.S. first, in April this year, under the name Foundayo. Lilly said in its third-quarter earnings report that it had brought in $281 million since launch. Lilly shares closed above $1,400 last night, up just over 0.3%—barely moving. With a market cap of more than $1.2 trillion, it’s just sitting there waiting for tonight’s premarket trading to deliver a verdict.
